Antimycobacterial drug discovery using Mycobacteria-infected amoebae identifies anti-infectives and new molecular targets

Research output: Contribution to journalArticle

Authors

  • Valentin Trofimov
  • Sébastien Kicka
  • Sabrina Mucaria
  • Nabil Hanna
  • Fernando Ramon-Olayo
  • Laura Vela-Gonzalez Del Peral
  • Joël Lelièvre
  • Lluís Ballell
  • Leonardo Scapozza
  • Jonathan A. G. Cox
  • Thierry Soldati

Colleges, School and Institutes

External organisations

  • Department of Biochemistry, Faculty of Science, University of Geneva
  • Pharmaceutical Biochemistry/Chemistry, School of Pharmaceutical Sciences, University of Geneva
  • GSK, Madrid
  • Aston University

Abstract

Tuberculosis remains a serious threat to human health world-wide, and improved efficiency of medical treatment requires a better understanding of the pathogenesis and the discovery of new drugs. In the present study, we performed a whole-cell based screen in order to complete the characterization of 168 compounds from the GlaxoSmithKline TB-set. We have established and utilized novel previously unexplored host-model systems to characterize the GSK compounds, i.e. the amoeboid organisms D. discoideum and A. castellanii, as well as a microglial phagocytic cell line, BV2. We infected these host cells with Mycobacterium marinum to monitor and characterize the anti-infective activity of the compounds with quantitative fluorescence measurements and high-content microscopy. In summary, 88.1% of the compounds were confirmed as antibiotics against M. marinum, 11.3% and 4.8% displayed strong anti-infective activity in, respectively, the mammalian and protozoan infection models. Additionally, in the two systems, 13-14% of the compounds displayed pro-infective activity. Our studies underline the relevance of using evolutionarily distant pathogen and host models in order to reveal conserved mechanisms of virulence and defence, respectively, which are potential "universal" targets for intervention. Subsequent mechanism of action studies based on generation of over-expresser M. bovis BCG strains, generation of spontaneous resistant mutants and whole genome sequencing revealed four new molecular targets, including FbpA, MurC, MmpL3 and GlpK.

Details

Original languageEnglish
Article number3939
JournalScientific Reports
Volume8
Issue number1
Publication statusPublished - 2 Mar 2018

Keywords

  • Journal Article, Pathogens , Phenotypic screening , target identification